-
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and DS-1062 to be Presented at the 2019 World Conference on Lung CancerDaiichi Sankyo2019-08-22 10:15:01Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and DS-1062 to
-
FDA Approves Daiichi Sankyo’s TURALIO® (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating TumorDaiichi Sankyo2020-08-03 09:31:50FDA Approves Daiichi Sankyo’s TURALIO® (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare
-
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C LoweringDaiichi Sankyo2019-08-07 13:30:01Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the
-
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AMLDaiichi Sankyo2020-08-03 09:32:24Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML
-
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual MeetingDaiichi Sankyo2019-08-07 13:30:01Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small
-
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual MeetingDaiichi Sankyo2019-08-07 13:30:01Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated
-
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology PortfolioDaiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of
-
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet NeedDaiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients
-
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric CancerDaiichi Sankyo2019-10-15 11:27:12Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-]
-
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLWDaiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of
